Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388669 · ClinicalTrials.gov registry record · Phase 3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
- 20
- Study locations
NCT05388669 is a Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 418 participants, above the 339-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (23% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05388669, a Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Conditions Studied
Interventions
- DRUG Lazertinib
- DRUG Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
- DRUG Amivantamab Intravenous
Study Locations (20)
California
- City of Hope Duarte - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- City of Hope Long Beach Elm - Long Beach
Other
- CEMIC (Centro de Educación Médica e Investigaciones Clínicas) - Buenos Aires
- Centro Oncológico Korben - Buenos Aires
- IADT Instituto Argentino de Diagnostico y Tratamiento - CABA
Florida
- Baptist Lynn Cancer Institute - Boca Raton
- Orlando Health - Orlando
New Jersey
- Astera Cancer Care - East Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center - New York
- Montefiore Medical Center - The Bronx
Oregon
- Providence Portland Medical Center - Portland
- Providence Oncology and Hematology Care Clinic Westside - Portland
Colorado
- National Jewish Health - Denver
Kansas
- University of Kansas - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388669
The ClinicalTrials.gov registry entry for NCT05388669 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 339-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (23% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Lazertinib is the first listed.
NCT05388669 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05388669 about?
NCT05388669 is a clinical study titled "A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer". The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the p...
What is the current status of trial NCT05388669?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2022-08-05. Estimated completion is 2027-06-30.
What conditions does trial NCT05388669 study?
This clinical trial studies the following conditions: Advanced or Metastatic Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT05388669?
The interventions under investigation include: Lazertinib (DRUG), Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (DRUG), Amivantamab Intravenous (DRUG).
Who is sponsoring clinical trial NCT05388669?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05388669 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.